Phase II evaluation of Gleevec [imatinib] combined with Camptosar [irinotecan] plus Paraplatin [carboplatin] in patients with previously untreated extensive stage SCLC [small cell lung cancer]
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2013
At a glance
- Drugs Imatinib (Primary) ; Carboplatin; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 08 Jan 2008 Status changed from in prgress to completed.
- 05 Nov 2005 New trial record.